Inari Medical, Inc. (NARI) has recently secured national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare for its ClotTriever Thrombectomy System, which is used to treat deep vein thrombosis (DVT).
Inari also established a distribution partnership with Medikit Co. Ltd, a well-known global medical device company, to support the launch of the ClotTriever system in Japan.
Inari Medical Makes Strides in Japan with ClotTriever Approval and Distribution Deal
What This Means for Inari Medical’s Stock
After these announcements, Inari’s shares remained unchanged at $52.12 on Monday. Yet, year-to-date, NARI’s shares have declined by 19.7%, contrasting with the industry‘s growth of 6.4%. Meanwhile, the S&P 500 has surged by 27.1% during the same period.
The new reimbursement approval and distribution partnership are expected to enhance ClotTriever sales in Japan and bolster overall revenues, which may particularly benefit the company’s stock price. Currently, Inari Medical has a market capitalization of $3.04 billion and has previously achieved an average earnings surprise of 24.8% over the past four quarters.
Image Source: Zacks Investment Research
Details on the ClotTriever System and Its Approval
The ClotTriever system is an FDA 510(k)-cleared and CE-marked mechanical thrombectomy device designed for DVT treatment. Recent results from the 500-patient ClotTriever CLOUT Registry demonstrated a low risk for post-thrombotic syndrome along with a high clot removal rate and safety profile. ClotTriever is highly regarded in the field, with ongoing studies like the Randomized Controlled Trial, DEFIANCE, which compares ClotTriever with anticoagulation therapy alone for DVT patients. The ClotTriever portfolio encompasses several variants, including ClotTriever Sheath 13F and 16F, ClotTriever BOLD, ClotTriever XL, and more.
In Japan, the ClotTriever system is categorized uniquely due to its effective thrombus elimination technique, differentiating it from traditional catheter-based therapies. The new reimbursement premium reflects the solid clinical evidence supporting its safety and effectiveness in treating various thrombi types.
Medikit, Inari’s distribution partner, is a leading manufacturer of vascular medical devices serving Japan, the United States, and over 30 additional countries. The collaboration aims to advance the initiation of a Post Market Surveillance study involving 100 patients, further expanding commercial efforts.
Expanding Inari’s Market Potential
Inari announced in December a joint venture with 6 Dimensions Capital and its successor fund, 120 Capital, alongside VFLO Medical, which focuses on addressing significant healthcare gaps in Greater China. This venture aims to leverage VFLO’s established network, local knowledge, and business skills to enhance commercialization efforts for Inari’s technologies. VFLO will also gain the ability to manufacture products for the domestic market in Greater China using Inari’s innovations.
Current Zacks Rank for NARI and Alternatives to Consider
Currently, NARI holds a Zacks Rank #3 (Hold).
Other noteworthy stocks within the medical sector include Masimo (MASI), AngioDynamics (ANGO), and Globus Medical (GMED).
Masimo has a Zacks Rank #1 (Strong Buy) and an estimated growth rate of 10.4% for 2025. The company has consistently surpassed earnings expectations, averaging a 17.10% surprise over the last four quarters. Its shares have appreciated by 37.2% year to date, compared to the industry’s 6.7% growth.
AngioDynamics, currently at Zacks Rank #2 (Buy), has a substantial estimated growth rate of 38.2% for 2025. Its earnings have exceeded estimates in three of the previous four quarters, yielding an average surprise of 31.71% despite an 8.9% decline in its share price so far this year.
Globus Medical, also rated #2 by Zacks, has an estimated long-term growth rate of 12.7%. Its earnings have beat the estimates across each of the last four quarters, achieving an average surprise of 12.1% and a remarkable 56.5% rise in share price year to date, relative to the industry’s growth of 6.7%.
Access Zacks’ Stock Insights for Just $1
We’re not kidding.
For a limited time, Zacks offers a 30-day access to all stock picks for just $1, allowing investors to explore various portfolio services without further obligation.
Many have taken advantage of this opportunity, recognizing the potential for significant gains. Zacks aims to help you discover insights into stocks like Surprise Trader, Stocks Under $10, Technology Innovators, and more, which reported 228 positions with double- and triple-digit gains in 2023 alone.
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
Read this article on Zacks.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
